Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic

Lancet

Volumn 348, Issue 9028, 1996, Pages 639-642

  Cheng, Katharine ^a   Smyth, Rosalind L ^a   Govan, John R W ^c   Doherty, Catherine ^c   Winstanley, Craig ^b   Denning, Nessa ^b   Heaf, David P ^a   Van Saene, Hendrik ^a   Hart, C Anthony ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Institute for Clean Growth and Future Mobility   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZLOCILLIN; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; RESTRICTION ENDONUCLEASE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; CROSS INFECTION; CYSTIC FIBROSIS; DNA FINGERPRINTING; DNA POLYMORPHISM; GENE AMPLIFICATION; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS;

EID: 0030573808     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05169-0     Document Type: Article

References (23)

1. 1 Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35-41.
2. 2 Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992; 48: 912-30.
3. 3 Govan JRW, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
4. + Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nature Med 1995; 1: 661-66.
5. 5 Grothues D, Kopman U, von der Hardt H, Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988; 26: 1973-77.
6. 6 Tummler B, Kooperman U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol 1991; 29: 1265-67.
7. 7 Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986; 17: 505-16.
8. 8 Speert DP, Davidson AGF, Wong LTK. Communicability of Pseudomonas aeruginosa in patients with cystic fibrosis. J Pediatr 1989; 114: 1068-69.
9. 9 The International Pseudomonas aeruginosa Typing Study Group. A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominantly from patients with cystic fibrosis. J Infect Dis 1994; 169: 134-42.
10. 10 Wolz C, Koisz G, Ogle JW, et al. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis use of DNA probe. Epidemiol Infect 1989; 102: 205-14.
11. 11 Hoogkamp-Korstanje JAA, van der Lang J. Incidence and risk of cross colonization in cystic fibrosis holiday camps. Antonie Van Leeuwenhoek 1980; 46: 100-01.
12. 12 Speert DP, Lawton D, Damn S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr 1982; 101: 227-29.
13. 13 Thomassen MJ, Demko CA, Klinger JD, Doershuk CF, Root JM. Pseudomonas aeruginosa isolates: comparison of isolates from campers and from sibling pairs with cystic fibrosis. Pediatr Pulmonol 1985; 1: 40-45.
14. 14 Speert DP, Campbell ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987; 9: 11-21.
15. 15 Bingen E, Botzenhart K, Chabanon G, et al. In: Doring E, Schaffer L, eds. Epidemiology of pulmonary infections by Pseudomonas in patients with cystic fibrosis: a consensus report. Paris: Association Francaise de lutte contre la Mucoviscidose, 1993.
16. 16 Govan JRW. Pseudomonas, Stenotrophomonas, Burkholderia. In: Collee JG, Fraser AG, Marmion BP, Simmons A, eds. Practical medical microbiology. New York: Churchill Livingstone, 1996: 413-24.
17. 17 National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. Approved Standard. Document M7-A2. Villanova USA: NCCLS, 1990.
18. 18 Butler SL, Doherty CJ, Hughes JE, Nelson JW, Govan JRW. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol 1995; 33: 1001-04.
19. 19 Winstanley C, Coulson MA, Wepner B, Morgan JAW, Hart CA. Flagellin gene and protein variation amongst clinical isolates of Pseudomonas aeruginosa. Microbiology 1996; 142: 2145-51.
20. 20 Dalzell AM, Sunderland D, Hart CA, Heaf DP. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces. Thorax 1991; 46: 239-41.
21. 21 Chen HY, Yuan M, Livermore DM. Mechanisms of resistance of β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995; 43: 300-09.
22. 22 Padoan R, Cambisaro W, Constantini D, et al. Ceftazidime monotherapy vs combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatr Infect Dis J 1987; 6: 7648-53.
23. 23 Ciofu O, Giwercman B, Pedersen SS, Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of anti-pseudomonal treatment at the Danish CF Center. Apmis 1994; 102: 674-80.